# Johan Vansteenkiste

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/johan-vansteenkiste/

## Facts

| Field | Value |
| --- | --- |
| Citations | 43,683 |
| Field | Lung Cancer Treatments and Mutations |
| h-index | 57 |
| i10-index | 136 |
| Last Known Institution | KU Leuven |
| OpenAlex ID | https://openalex.org/A5107385450 |
| ORCID iD | https://orcid.org/0000-0002-6721-2775 |
| Works | 266 |

## Researcher papers

Showing 12 of 15.

- [Osimertinib in Untreated <i>EGFR</i> -Mutated Advanced Non–Small-Cell Lung Cancer](https://scholariq.org/papers/osimertinib-in-untreated-i-egfr-i-mutated-advanced-non-small-cell-lung-cancer/)
- [Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer](https://scholariq.org/papers/phase-iii-study-comparing-cisplatin-plus-gemcitabine-with-cisplatin-plus/)
- [Overall Survival with Osimertinib in Untreated, <i>EGFR</i> -Mutated Advanced NSCLC](https://scholariq.org/papers/overall-survival-with-osimertinib-in-untreated-i-egfr-i-mutated-advanced-nsclc/)
- [Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC](https://scholariq.org/papers/overall-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc/)
- [Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial](https://scholariq.org/papers/atezolizumab-versus-docetaxel-for-patients-with-previously-treated-non-small/)
- [Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up](https://scholariq.org/papers/metastatic-non-small-cell-lung-cancer-esmo-clinical-practice-guidelines-for/)
- [Ceritinib in <i>ALK</i> -Rearranged Non–Small-Cell Lung Cancer](https://scholariq.org/papers/ceritinib-in-i-alk-i-rearranged-non-small-cell-lung-cancer/)
- [Capmatinib in <i>MET</i> Exon 14–Mutated or <i>MET</i> -Amplified Non–Small-Cell Lung Cancer](https://scholariq.org/papers/capmatinib-in-i-met-i-exon-14-mutated-or-i-met-i-amplified-non-small-cell-lung/)
- [Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆](https://scholariq.org/papers/small-cell-lung-cancer-esmo-clinical-practice-guidelines-for-diagnosis-treatment/)
- [Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study](https://scholariq.org/papers/durvalumab-as-third-line-or-later-treatment-for-advanced-non-small-cell-lung/)
- [Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/efficacy-of-the-mage-a3-cancer-immunotherapeutic-as-adjuvant-therapy-in-patients/)
- [Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial](https://scholariq.org/papers/four-year-survival-with-durvalumab-after-chemoradiotherapy-in-stage-iii-nsclc-an/)

## Researcher topics

- [Lung Cancer Treatments and Mutations](https://scholariq.org/topics/lung-cancer-treatments-and-mutations/)
- [Lung Cancer Research Studies](https://scholariq.org/topics/lung-cancer-research-studies/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Lung Cancer Diagnosis and Treatment](https://scholariq.org/topics/lung-cancer-diagnosis-and-treatment/)
- [Colorectal Cancer Treatments and Studies](https://scholariq.org/topics/colorectal-cancer-treatments-and-studies/)

## Researcher university

- [KU Leuven](https://scholariq.org/institutions/ku-leuven/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.